New PBS meds

Pharmacy Daily - - NEWS -

FED­ERAL Health Min­is­ter Greg Hunt has an­nounced ad­di­tional PBS funding to sup­port leukaemia and acromegaly pa­tients.

Zy­delig (de­lal­isib) from Gilead will be made avail­able to treat el­i­gi­ble pa­tients with cer­tain types of leukaemia, in­clud­ing re­lapsed or re­frac­tory chronic lym­pho­cytic leukaemia or small lym­pho­cytic leukaemia while also help­ing pa­tients with re­lapsed or re­frac­tory fol­lic­u­lar lym­phoma.

tithout sub­sidy, the treat­ment would cost be­tween $60,500 and $115,800 per year per pa­tient.

Pfizer’s So­mavert (pegvi­so­mant) is also listed for pa­tients suf­fer­ing from Acromegaly, a rare con­di­tion char­ac­terised by a con­sis­tently high level of cir­cu­lat­ing growth hor­mone.

Full de­tails avail­able at pbs.gov.au.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.